NervGen Pharma Corp. NGEN
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.25% | -3.32% | 26.88% | -39.07% | 48.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.20% | 30.56% | -5.51% | -15.44% | -2.38% |
| Operating Income | -100.20% | -30.56% | 5.51% | 15.44% | 2.38% |
| Income Before Tax | 220.00% | 55.60% | -213.86% | 22.29% | -13.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 220.00% | 55.60% | -213.86% | 22.29% | -13.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 220.00% | 55.60% | -213.86% | 22.29% | -13.72% |
| EBIT | -100.20% | -30.56% | 5.51% | 15.44% | 2.38% |
| EBITDA | -100.44% | -30.62% | 5.50% | 15.46% | 2.37% |
| EPS Basic | 193.36% | 60.67% | -198.75% | 25.63% | -10.51% |
| Normalized Basic EPS | 193.45% | 60.49% | -198.91% | 25.43% | -10.57% |
| EPS Diluted | 1.60% | -59.57% | -198.75% | 25.63% | -14.91% |
| Normalized Diluted EPS | 182.12% | 61.32% | -198.91% | 25.43% | -10.57% |
| Average Basic Shares Outstanding | 28.47% | 13.07% | 5.03% | 4.41% | 2.87% |
| Average Diluted Shares Outstanding | 46.07% | 14.43% | 5.03% | 4.41% | 2.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |